Month: February 2022

Formation of a Scientific Advisory Board

Ermium Therapeutics SAS, a discovery-stage biotechnology company developing innovative therapies for auto-immune diseases, is announcing today the expansion of the Company management team with the appointment of Dr Hélène Asnagli as Head of Biology/Pharmacology. Dr Asnagli brings strong expertise in non-clinical R&D for auto-immune diseases.